Phospho-VAV3 (Tyr173) Antibody

What is the VAV3 (phospho Tyr173) antibody and what does it detect?

The VAV3 (phospho Tyr173) antibody is a polyclonal antibody that specifically recognizes VAV3 protein when phosphorylated at tyrosine 173. VAV3 is a multi-domain tyrosine phosphorylation-dependent Rac guanine nucleotide exchange factor (RacGEF) that functions downstream of several different signaling molecules. This antibody allows researchers to detect the activated form of VAV3, as phosphorylation at Tyr173 is a key event in releasing the autoinhibitory conformation of VAV3, enabling its GEF activity toward RAC GTPases . The antibody has been validated for use in Western blotting applications and shows specific reactivity with mouse specimens, making it suitable for studying VAV3 activation in murine experimental models .

What is the structural and functional significance of Tyr173 phosphorylation in VAV3?

Tyrosine 173 phosphorylation holds crucial significance in VAV3 function and regulation. Structurally, VAV3 can be divided into two major regions: an N-terminal half containing the RAC-binding region and a C-terminal adaptor module . The N-terminal region includes a calponin homology (CH) domain and an acidic stretch (Ac) that maintain VAV3 in an autoinhibited state. Phosphorylation of conserved tyrosine residues, including Tyr173 in the acidic region, releases this autoinhibition through conformational changes . This structural rearrangement allows GTPase access to the Dbl homology (DH) domain, enabling VAV3's GEF activity. The functional consequence is activation of RAC signaling cascades, affecting processes like cytoskeletal reorganization and cellular proliferation that are particularly important in hematopoietic cells and cancer development .

How is the specificity of VAV3 (phospho Tyr173) antibody validated in experimental settings?

Validation of the VAV3 (phospho Tyr173) antibody specificity involves multiple experimental approaches to ensure selective detection of phosphorylated VAV3. Western blot peptide competition assays provide compelling evidence for antibody specificity. In these experiments, Cos7 cells overexpressing murine Vav3 were serum-starved and then treated with EGF to induce phosphorylation. The antibody was pre-incubated with different peptides: non-phospho immunogen, generic phosphotyrosine (pY) peptide, or the phosphopeptide immunogen used to generate the antibody . Results demonstrated that only the phosphopeptide immunogen successfully blocked the antibody signal, confirming its specific recognition of phosphorylated Tyr173 on VAV3 . This validation is essential for researchers to confidently interpret experimental results involving phosphorylation status of VAV3.

What experimental models are suitable for studying VAV3 phosphorylation at Tyr173?

Several experimental models have been validated for studying VAV3 phosphorylation at Tyr173. Cell lines such as Cos7 cells overexpressing murine Vav3 provide a controlled system for studying VAV3 phosphorylation dynamics in response to stimuli like EGF . Murine bone marrow-derived leukemic cells expressing BCR-ABL1 (p190 or p210 variants) have been effectively used to study VAV3 activation and its role in leukemogenesis . Patient-derived xenograft (PDX) models of Philadelphia chromosome-positive (Ph+) and Ph-like B-cell acute lymphoblastic leukemia (B-ALL) have also demonstrated utility for investigating VAV3 phosphorylation in a clinically relevant context . In research requiring genetic manipulation of VAV3, both wild-type and Vav3 knockout mouse models offer valuable comparative systems to establish specificity of effects and validate experimental findings related to VAV3 function and phosphorylation .

How can phospho-VAV3 (Tyr173) antibody be used to investigate VAV3-dependent signaling pathways in cancer?

The phospho-VAV3 (Tyr173) antibody serves as a powerful tool for dissecting VAV3-dependent signaling networks in cancer, particularly in hematological malignancies. Researchers can employ this antibody to monitor VAV3 activation status before and after treatment with pathway inhibitors to establish signaling hierarchies. Studies have demonstrated that phospho-VAV3 levels correlate with activation of downstream effectors including PAK1/2/3, JNK, 4EBP, and S6, which can be simultaneously monitored to establish complete pathway activation profiles . In BCR-ABL1-driven leukemias, investigators have used this antibody to demonstrate that VAV3 phosphorylation status correlates with leukemic cell proliferation and survival capacity . Interestingly, research has shown that some tyrosine kinase inhibitors (TKIs) like dasatinib fail to effectively inhibit VAV3 phosphorylation despite targeting upstream kinases, suggesting complex regulatory mechanisms . This finding highlights the value of directly monitoring VAV3 phosphorylation rather than inferring its status from upstream pathway components.

What methodological approaches can be used to assess the functional consequences of VAV3 phosphorylation at Tyr173?

Multiple methodological approaches can effectively assess the functional consequences of VAV3 Tyr173 phosphorylation. Colony-forming assays provide a robust readout of the biological impact of VAV3 phosphorylation on cellular proliferation and self-renewal. Research has shown that wild-type leukemic bone marrow cells display significantly reduced colony formation when treated with VAV3 inhibitors, while Vav3-null cells remain unaffected, demonstrating the functional relevance of VAV3 signaling . Cell cycle analysis by flow cytometry can quantify changes in proliferation and apoptosis rates following modulation of VAV3 phosphorylation status . Biochemical approaches include measuring activation of RAC and its downstream effectors (pJNK, pPAK1/2/3, p4EBP, pS6) by immunoblotting to establish signaling consequences . For in vivo functional assessment, researchers can isolate primary cells from treated animals and perform ex vivo analyses of VAV3 phosphorylation alongside functional readouts such as leukemic cell engraftment potential, providing a comprehensive evaluation of VAV3's role in disease maintenance and progression .

How does phosphorylation at Tyr173 coordinate with other post-translational modifications of VAV3?

Phosphorylation at Tyr173 operates within a complex network of post-translational modifications that collectively regulate VAV3 function. The acidic region of VAV3 contains multiple conserved tyrosine residues that undergo phosphorylation, with Tyr173 being a critical site . Research suggests a sequential model of VAV3 activation where initial phosphorylation events trigger conformational changes that expose additional tyrosine residues for subsequent phosphorylation. While the phospho-VAV3 (Tyr173) antibody specifically recognizes this single modification, comprehensive understanding of VAV3 regulation requires consideration of the phosphorylation status at multiple sites simultaneously . The functional output of VAV3 appears to depend on the specific combination of phosphorylated residues, which may direct VAV3 toward distinct downstream pathways. Additionally, VAV3 function can be modulated by other types of post-translational modifications and protein-protein interactions, particularly with its C-terminal SH2/SH3 adaptor domains, although these domains are not required for binding of certain inhibitors like IODVA1 .

What is the relationship between VAV3 phosphorylation at Tyr173 and treatment resistance in cancer therapy?

VAV3 phosphorylation at Tyr173 has emerged as a significant biomarker associated with treatment resistance in cancer therapy, particularly in hematological malignancies. Research using patient-derived xenograft (PDX) models of Philadelphia chromosome-positive (Ph+) B-cell acute lymphoblastic leukemia (B-ALL) demonstrates a strong correlation between high levels of phosphorylated VAV3 and resistance to tyrosine kinase inhibitors (TKIs) such as dasatinib and ponatinib . Importantly, studies have shown that dasatinib, despite targeting BCR-ABL1 and SRC-family kinases involved in VAV3 activation, fails to effectively inhibit VAV3 phosphorylation at Tyr173 . This suggests that persistent VAV3 activation may serve as an escape mechanism from targeted therapies. In PDX models, phospho-VAV3 levels decrease during effective treatment but increase upon treatment cessation, correlating with disease recurrence . These findings indicate that monitoring VAV3 phosphorylation status could potentially serve as a predictive biomarker for treatment response and that directly targeting VAV3 or its downstream effectors might overcome resistance to conventional therapies in certain cancer types.

What are the optimal experimental conditions for detecting phospho-VAV3 (Tyr173) in Western blot applications?

Detection of phospho-VAV3 (Tyr173) in Western blot applications requires careful optimization of experimental conditions to ensure specific and sensitive signal detection. Based on validated protocols, researchers should include phosphatase inhibitors in lysis buffers to preserve the phosphorylation status during sample preparation . Serum starvation of cells prior to stimulation with growth factors like EGF enhances the signal-to-noise ratio by reducing baseline phosphorylation . For optimal results, protein samples should be resolved on 8-10% SDS-PAGE gels to effectively separate the VAV3 protein (approximately 97 kDa). Transfer conditions should be optimized for high molecular weight proteins, typically using lower current for longer duration . When probing membranes, the recommended antibody dilution for GTX24764 should be determined empirically, but typically ranges between 1:500 to 1:1000 in 5% BSA/TBST . Including positive controls (EGF-stimulated cells overexpressing VAV3) and negative controls (unstimulated cells or phosphatase-treated lysates) in each experiment provides critical reference points for data interpretation and confirms antibody specificity .

How can researchers distinguish between VAV3 phosphorylation at Tyr173 and other VAV family members?

Distinguishing between phosphorylation of VAV3 at Tyr173 and similar modifications on other VAV family members (VAV1 and VAV2) requires careful experimental design and controls due to potential cross-reactivity. While the phospho-VAV3 (Tyr173) antibody is designed for specificity, researchers should implement additional validation steps in their experiments. One essential approach is to confirm antibody specificity by comparing signals in wild-type and Vav3 knockout cells or tissues, as demonstrated in studies where Vav3-null leukemic cells showed no response to treatments affecting VAV3 phosphorylation . Peptide competition assays provide another validation method, where pre-incubation with the specific phosphopeptide immunogen should abolish the signal if truly specific for phospho-VAV3 . Western blot analysis can also assess whether the antibody detects bands of molecular weights corresponding to other VAV family members. Research has shown that treatment with the VAV3 inhibitor IODVA1 does not affect phosphorylation levels of VAV1, indicating distinct regulation of these family members . For definitive studies, researchers should consider using multiple antibodies targeting different epitopes or phosphorylation sites to confirm the identity of the detected protein.

What complementary techniques can validate phospho-VAV3 (Tyr173) antibody findings in research applications?

Multiple complementary techniques can strengthen and validate findings obtained using the phospho-VAV3 (Tyr173) antibody. Mass spectrometry represents the gold standard for validating specific phosphorylation sites, providing unambiguous identification of Tyr173 phosphorylation on VAV3 peptides. Functional validation through genetic approaches is equally critical; comparing responses between wild-type and Vav3 knockout cells to treatments affecting VAV3 signaling can confirm antibody specificity and biological relevance . Expression of various VAV3 mutants, such as the tyrosine-to-phenylalanine mutant at position 173, in Vav3-null cells can further validate the specificity of the antibody and the importance of this specific phosphorylation site . Pull-down assays using modified tools like biotinylated inhibitors that bind to VAV3 can be performed with subsequent immunoblotting for phospho-VAV3 to confirm target engagement . Measuring downstream signaling events, such as RAC activation status via RAC-GTP pull-down assays or phosphorylation of effectors like PAK1/2/3 and JNK, provides functional validation of VAV3 activity that should correlate with Tyr173 phosphorylation status .

What methodological approaches can assess VAV3 Tyr173 phosphorylation in primary patient samples?

Assessing VAV3 Tyr173 phosphorylation in primary patient samples requires specialized methodological approaches that address the challenges of limited material and heterogeneous cell populations. Western blotting remains a fundamental technique when sufficient material is available, with studies successfully detecting phospho-VAV3 in bone marrow aspirates from leukemia patients . Patient-derived xenograft (PDX) models provide an alternative approach, allowing expansion of primary cells while maintaining their biological characteristics; research has demonstrated correlation between phospho-VAV3/VAV3 levels in these models and response to targeted therapies . For smaller samples, phospho-flow cytometry offers a sensitive method to detect phospho-VAV3 at the single-cell level, enabling analysis of specific cell populations within heterogeneous samples. Importantly, proper validation of each method is crucial; studies have shown that high levels of phospho-VAV3 in patient-derived leukemia cells correlate with their sensitivity to VAV3 inhibitors, while samples with low phospho-VAV3 showed reduced response . These findings suggest that phospho-VAV3 levels may serve as a biomarker for patient stratification in clinical settings, highlighting the importance of robust methods for its assessment.

How should researchers address potential false positives or negatives when using phospho-VAV3 (Tyr173) antibody?

Addressing potential false results when using phospho-VAV3 (Tyr173) antibody requires systematic validation approaches and appropriate controls. For false positives, researchers should perform peptide competition assays where pre-incubation of the antibody with the phospho-Tyr173 peptide should eliminate specific signals, while non-phosphorylated peptides or generic phosphotyrosine peptides should not affect specific binding . This approach has been validated in studies showing that only the immunogen phosphopeptide blocks the signal, confirming antibody specificity . For false negatives, researchers should include positive controls such as cell lysates from EGF-stimulated cells known to induce VAV3 phosphorylation . Sample preparation issues like insufficient phosphatase inhibition can lead to loss of phosphorylation; therefore, freshly prepared samples with complete protease and phosphatase inhibitor cocktails are recommended. When interpreting borderline results, researchers should cross-validate with other readouts of VAV3 activity, such as downstream effector phosphorylation (pPAK1/2/3, pJNK) . If conflicting results emerge between the antibody signal and expected biological outcomes, genetic validation using Vav3 knockout models or VAV3-depleted cells can provide definitive evidence for antibody specificity and signal interpretation .

How can researchers correlate VAV3 phosphorylation status with functional outcomes in signaling pathways?

Correlating VAV3 phosphorylation status with functional outcomes in signaling pathways requires multi-parametric analysis and carefully designed experimental workflows. Researchers should implement a systematic approach that pairs phospho-VAV3 (Tyr173) detection with measurements of downstream effector activation. Studies have established key VAV3-dependent signaling nodes including RAC activation and subsequent phosphorylation of PAK1/2/3, JNK, 4EBP, and S6, while ERK, p38, STAT3, STAT5, and AKT phosphorylation appear to be VAV3-independent . This differentiation allows researchers to confirm VAV3-specific effects. Functional cellular outcomes should also be assessed in parallel through proliferation assays, apoptosis measurements, and cell cycle analysis . The causal relationship between VAV3 phosphorylation and observed effects can be validated through rescue experiments, where re-expression of wild-type VAV3 in Vav3-null cells restores sensitivity to treatments affecting this pathway, while expression of exchange-deficient mutants (N369A) or constitutively active forms (ΔCH) provides mechanistic insights . Studies have demonstrated this approach by showing that only full-length VAV3, not the exchange-deficient mutant, restored sensitivity to the VAV3 inhibitor IODVA1 in Vav3-knockout cells .

What factors might influence variability in phospho-VAV3 (Tyr173) detection across different experimental systems?

Multiple factors can contribute to variability in phospho-VAV3 (Tyr173) detection across experimental systems, requiring careful consideration during experimental design and data interpretation. Cell type-specific differences in VAV3 expression levels and regulatory mechanisms significantly impact detection sensitivity, as demonstrated by varying responses to VAV3 inhibition across different patient-derived xenograft models . The activation state of upstream kinases, particularly SRC-family kinases responsible for VAV3 phosphorylation, can vary dramatically between experimental conditions and cell types. Culture conditions including serum levels, cell density, and duration of treatments can affect baseline phosphorylation and response magnitude . Technical factors such as antibody lot variability, protein extraction methods, and phosphatase inhibitor effectiveness all contribute to experimental variation . Studies showing different phospho-VAV3 levels between patient samples with identical genetic alterations (e.g., IGH-CLRF2; JAK2 mutations) highlight the importance of validating each experimental system individually . Cross-validation using complementary detection methods can help distinguish biological variability from technical artifacts. Researchers should consider time-course experiments to capture the dynamic nature of phosphorylation events, as VAV3 activation may be transient or sustained depending on the cellular context and stimulus type.

How can phospho-VAV3 (Tyr173) antibody be used to monitor therapeutic responses in research models?

The phospho-VAV3 (Tyr173) antibody serves as a valuable tool for monitoring therapeutic responses in research models, particularly in the context of targeted cancer therapies. Experimental designs should include baseline measurements of phospho-VAV3 levels before treatment initiation, followed by time-course sampling during and after treatment to track dynamic changes in VAV3 activation status . Studies in patient-derived xenograft (PDX) models have demonstrated that phospho-VAV3 levels provide a more reliable indicator of therapeutic response than upstream kinase inhibition alone; for example, the ABL1-TKI dasatinib failed to effectively inhibit VAV3 phosphorylation despite targeting upstream kinases, explaining its limited efficacy . For comprehensive pathway monitoring, researchers should simultaneously assess phospho-VAV3 levels alongside its downstream effectors pPAK1/2 and pJNK, which show correlated responses to effective treatments . In longitudinal studies, phospho-VAV3 levels have been shown to decrease during effective treatment periods but increase upon treatment cessation, correlating with disease recurrence . This pattern validates phospho-VAV3 as both a response biomarker and a potential indicator of relapse. For most robust results, researchers should extract bone marrow aspirates or peripheral blood samples at consistent time points and process them immediately with standardized protocols to minimize technical variability.

What emerging technologies could enhance the detection and quantification of phospho-VAV3 (Tyr173) in complex biological samples?

Several emerging technologies hold promise for improving phospho-VAV3 (Tyr173) detection in complex biological samples. Digital immunoassay platforms utilizing single molecule array (Simoa) technology could dramatically enhance sensitivity, potentially enabling detection of phospho-VAV3 in liquid biopsies or minimal residual disease samples from cancer patients. Mass cytometry (CyTOF) combined with phospho-specific antibodies would allow simultaneous detection of phospho-VAV3 alongside dozens of other phosphorylation events at the single-cell level, providing comprehensive pathway activation profiles in heterogeneous samples . Proximity ligation assays (PLA) offer another promising approach for detecting phospho-VAV3 in tissue sections or fixed cells with enhanced specificity by requiring dual recognition of VAV3 protein and the phospho-tyrosine moiety. CRISPR-based biosensors that produce detectable signals upon VAV3 phosphorylation could enable real-time monitoring in living cells. For absolute quantification, targeted mass spectrometry approaches using multiple reaction monitoring (MRM) or parallel reaction monitoring (PRM) of signature peptides containing phosphorylated Tyr173 would provide unparalleled specificity and quantitative accuracy . These advanced technologies could overcome current limitations in detecting phospho-VAV3 in rare cell populations or samples with limited material availability.

How might phospho-VAV3 (Tyr173) status serve as a biomarker in translational research applications?

Phospho-VAV3 (Tyr173) status shows significant potential as a biomarker in translational research applications, particularly in hematological malignancies and potentially other cancer types. Research has demonstrated that phospho-VAV3 levels correlate with sensitivity to VAV3 inhibitors in patient-derived samples, suggesting utility as a predictive biomarker for patient stratification in clinical trials . Studies in Philadelphia chromosome-positive (Ph+) and Ph-like B-cell acute lymphoblastic leukemia (B-ALL) have shown that high levels of phospho-VAV3 correspond with aggressive disease features and resistance to conventional tyrosine kinase inhibitors, indicating potential prognostic value . The dynamic nature of VAV3 phosphorylation during treatment and its correlation with disease recurrence after treatment cessation positions it as a candidate biomarker for monitoring minimal residual disease and early detection of relapse . For clinical implementation, standardized immunohistochemistry or immunofluorescence protocols using phospho-VAV3 (Tyr173) antibody could enable routine assessment in diagnostic pathology laboratories. Development of clinical-grade assays would require rigorous validation of pre-analytical variables, reproducibility across different laboratories, and establishment of quantitative thresholds corresponding to clinical outcomes, representing an important frontier in translational VAV3 research.

What novel therapeutic strategies might emerge from understanding VAV3 phosphorylation mechanisms?

Understanding VAV3 phosphorylation mechanisms is driving the development of novel therapeutic strategies with potential applications across multiple cancer types. Direct inhibition of VAV3 by small molecules like IODVA1, which binds to VAV3 with a Kd of 512 nM and prevents its phosphorylation and subsequent activation, represents a pioneering approach . This strategy has shown superior efficacy compared to upstream kinase inhibitors in tyrosine kinase inhibitor (TKI)-resistant leukemia models . Structural biology insights suggest that IODVA1 likely locks VAV3 into its autoinhibitory conformation, preventing access of the Dbl homology (DH) domain to RAC GTPases . This mechanistic understanding could guide development of next-generation inhibitors with improved potency and pharmacokinetic properties. Alternative approaches might include targeting the VAV3/RAC interface directly or developing proteolysis-targeting chimeras (PROTACs) to induce VAV3 degradation. Combination strategies targeting VAV3 alongside complementary pathways show particular promise; research has demonstrated that combining the VAV3 inhibitor IODVA1 with ponatinib provided superior and more durable responses in patient-derived xenograft models compared to either agent alone . Screening patient samples for phospho-VAV3 status could enable precision medicine approaches, directing VAV3-targeting therapies to those most likely to benefit based on pathway activation status.